evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,495 questions · 1,554 findings · 140 reviews · Heart

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 272 · 17.5%GRADE not reported 44 · 2.8%Very low 329 · 21.2%Low 464 · 29.9%Moderate 319 · 20.5%High 126 · 8.1%

Ranolazine (monotherapy) vs placebo

All‐cause mortality · patients with stable angina pectoris

Ranolazine (monotherapy) showed no clear difference in all‐cause mortality compared with placebo (low certainty).

1 finding from 1 review

Ranolazine (monotherapy) vs placebo

Adverse events incidence · patients with stable angina pectoris

It is very uncertain whether ranolazine (monotherapy) changes adverse events incidence compared with placebo (very low certainty).

1 finding from 1 review

Ranolazine (monotherapy) vs placebo

Cardiovascular mortality · patients with stable angina pectoris

Ranolazine (monotherapy) showed no clear difference in cardiovascular mortality compared with placebo (low certainty).

1 finding from 1 review

Complete revascularisation vs culprit‐only revascularisation

Long‐term all‐cause mortality (≥ 1 year after the intervention) · people with STEMI and MVD.

It is very uncertain whether complete revascularisation changes long‐term all‐cause mortality (≥ 1 year after the intervention) compared with culprit‐only revascularisation (very low certainty).

1 finding from 1 review

Complete revascularisation vs culprit‐only revascularisation

Cardiovascular mortality · people with STEMI and MVD.

It is very uncertain whether complete revascularisation changes long‐term cardiovascular mortality (≥ 1 year after the intervention) compared with culprit‐only revascularisation (very low certainty).

1 finding from 1 review

Complete revascularisation vs culprit‐only revascularisation

Myocardial infarction · people with STEMI and MVD.

It is very uncertain whether complete revascularisation changes long‐term myocardial infarction (≥ 1 year after the intervention) compared with culprit‐only revascularisation (very low certainty).

1 finding from 1 review

Complete revascularisation vs culprit‐only revascularisation

Overall adverse events (pooled short and long term) · people with STEMI and MVD.

It is very uncertain whether complete revascularisation changes overall adverse events (pooled short and long term) compared with culprit‐only revascularisation (very low certainty).

1 finding from 1 review

Complete revascularisation vs culprit‐only revascularisation

Short‐term all‐cause mortality (within the first 30 days after the intervention) · people with STEMI and MVD.

It is very uncertain whether complete revascularisation changes short‐term all‐cause mortality (within the first 30 days after the… compared with culprit‐only revascularisation (very low certainty).

1 finding from 1 review

Complete revascularisation vs culprit‐only revascularisation

Long‐term revascularisation (≥ 1 year after the intervention) · people with STEMI and MVD.

It is very uncertain whether complete revascularisation changes long‐term revascularisation (≥ 1 year after the intervention) compared with culprit‐only revascularisation (very low certainty).

1 finding from 1 review